Indorama Ventures to Buy INVISTA’s PET Polymer and Resins Manufacturing Plants

Indorama Ventures Public Company Limited announced today that it has signed a definitive agreement to acquire PET polymer and resins manufacturing facilities located in Spartanburg, S.C. and Querétaro, Mexico from certain subsidiaries of INVISTA B.V.

The total value of the acquisition will be $420 million less certain assumed liabilities, and includes $229 million for the net fixed assets and equity interests, as well as $174 million for the net working capital of the business, subject to customary adjustments at closing. The transaction is expected to be financed from a combination of cash on hand, amounts available under existing credit facilities and additional debt. The parties anticipate the transaction will close in the first quarter of 2011, pending receipt of necessary regulatory approvals.

INVISTA’s Spartanburg, South Carolina facility produces polyester resins used in bottles for carbonated soft drinks, water, beer, juice, and wine; food and custom-container applications, and polyester staple fiber and specialty polymers for a variety of applications. The Spartanburg operation has a total capacity of 470 kMT per annum. Approximately 490 people are employed at the site.

INVISTA’s Querétaro, Mexico facility produces polyester resins and polyester staple similar to that produced at INVISTA’s Spartanburg operation. Querétaro has a total capacity of 535 kMT per annum. Approximately 510 people are employed at the site.

The combination positions Indorama Ventures as the world’s leading producer of PET and enables IVL to better meet its customers’ needs. In North America, the acquisition complements Indorama Ventures’ existing PET manufacturing site at Asheboro, N.C. (StarPET) and its state-of-the-art MTR PET Resin facility at Decatur, Alabama (AlphaPET). Additional benefits for IVL will include:

  • Access to new customers and markets via Querétaro
  • Entry into the U.S. specialty PET fibers market via Spartanburg
  • Enhancement of research and development capabilities
  • Benefit from integration with IVL’s existing facilities, including AlphaPET and StarPET
  • Increased production flexibility

The transaction is expected to be accretive to IVL’s earnings in the first full year of acquisition (pre-synergies). Indorama Ventures believes that there is a further opportunity to create value for its shareholders through synergy capture.

“We believe INVISTA’s Spartanburg and Querétaro businesses complement Indorama Ventures’ existing U.S. business,” said Chris Hamman, president of INVISTA Polymer & Resins. “I want to extend thanks and appreciation to all INVISTA employees involved in our polymer and resins business for their dedication through this process, and for building a business that so capably delivers innovation and value to its customers.”

“This planned acquisition will allow IVL to build upon our expanding global platform, make the company the largest PET producer in the world, and deliver on our strategy to enter into new higher growth regions like Central and Latin America,” said Aloke Lohia, Group Chief Executive Officer of Indorama Ventures. “We believe these valuable assets will further strengthen our capability and reinforce our ongoing commitment to the PET and Fiber business. We are truly excited as such million ton opportunities are seldom available. Furthermore, INVISTA’s innovative products and a recognized brand will allow Indorama Ventures to enhance its value proposition to its customers and stakeholders, considering the depth of management and knowledge that reside at these facilities supporting manufacturing, R&D and Post Consumer Recycling (PCR),” added Mr. Lohia.

It is currently anticipated that essentially all of INVISTA’s Polymer & Resins’ operations, marketing, sales, customer service, and research and development staff associated with the Spartanburg and Querétaro operations will be employed by Indorama after the sale is finalized, along with INVISTA Polymer & Resins’ staff associated with that portion of the business based at administrative offices in Charlotte, North Carolina; and Santa Fe, Mexico.

INVISTA Polymer & Resins’ Wilmington, N.C. site is not a part of the transaction, nor is INVISTA’s European Polymer & Resins business, which includes manufacturing operations in Gersthofen, Germany. INVISTA will also retain certain intellectual property related to the polymer and resins business.

Deutsche Bank Securities Inc. acted as exclusive financial advisor, Lowenstein Sandler PC acted as lead counsel, and Jáuregui Navarrete y Nader, S.C. served as Mexican counsel to IVL on this transaction. On behalf of INVISTA, Morgan Stanley & Co. Incorporated acted as exclusive financial advisor and Latham & Watkins LLP acted as lead counsel.

Source: http://www.invista.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    INVISTA. (2019, February 10). Indorama Ventures to Buy INVISTA’s PET Polymer and Resins Manufacturing Plants. AZoM. Retrieved on April 18, 2024 from https://www.azom.com/news.aspx?newsID=25822.

  • MLA

    INVISTA. "Indorama Ventures to Buy INVISTA’s PET Polymer and Resins Manufacturing Plants". AZoM. 18 April 2024. <https://www.azom.com/news.aspx?newsID=25822>.

  • Chicago

    INVISTA. "Indorama Ventures to Buy INVISTA’s PET Polymer and Resins Manufacturing Plants". AZoM. https://www.azom.com/news.aspx?newsID=25822. (accessed April 18, 2024).

  • Harvard

    INVISTA. 2019. Indorama Ventures to Buy INVISTA’s PET Polymer and Resins Manufacturing Plants. AZoM, viewed 18 April 2024, https://www.azom.com/news.aspx?newsID=25822.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.